Asuragen Awarded $6.8M to Commercialize Sequencing-Based Cancer Dx Tests | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Diagnostic company Asuragen has been awarded a $6.8 million grant from the Cancer Prevention and Research Institute of Texas to commercialize next-generation sequencing-based cancer tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.